ELCC 2020 INDUSTRY SATELLITE SYMPOSIUM

Looking Closely at the Options for the Patient With Advanced ALK-Positive NSCLC CME

THURSDAY, 16 APRIL 2020

TIME: 18:00 – 19:00

VENUE: PALEXPO, GENEVA, SWITZERLAND | ROOM A

A Medscape LIVE! EVENT

MODERATOR
Sanjay Popat, PhD, FRCP
Consultant Medical Oncologist
Royal Marsden Hospital
Professor of Thoracic Oncology
The Institute of Cancer Research
London, United Kingdom

PANELISTS
Ross Camidge, MD, PhD
Director of Thoracic Oncology
University of Colorado
Aurora, Colorado, United States

Rosario García Campelo, MD
Medical Oncology Unit
Head of Clinical Research Unit
University Hospital A Coruña
INIBIC
A Coruña, Spain

AGENDA

18:00
With More Options Come More Questions: Challenges for the Patient With De Novo ALK-Positive Metastatic NSCLC
Sanjay Popat, PhD, FRCP

Debating the First-Line Treatment Options for the Patient With ALK-Positive Metastatic NSCLC
Sanjay Popat, PhD, FRCP

18:10
What Do the Latest Clinical Trial Data Show Regarding the Efficacy and Safety of ALK Inhibitors in the First Line?
Ross Camidge, MD, PhD and Rosario García Campelo, MD
Moderated by Sanjay Popat, PhD, FRCP

18:25
What About Quality of Life and Other Patient Factors?
Ross Camidge, MD, PhD and Rosario García Campelo, MD
Moderated by Sanjay Popat, PhD, FRCP

18:35
Anticipating, Monitoring, and Managing Adverse Events
Ross Camidge, MD, PhD and Rosario García Campelo, MD
Moderated by Sanjay Popat, PhD, FRCP

18:50
So Which ALK Inhibitor for Which Patient?
Ross Camidge, MD, PhD and Rosario García Campelo, MD
Moderated by Sanjay Popat, PhD, FRCP

19:00
Concluding Remarks and Close
Sanjay Popat, PhD, FRCP

Supported by independent funding from:

Takeda

Medscape ONCOLOGY GLOBAL